Table 1 Baseline characteristics of the children according to antiretroviral treatment outcome group

Number (%)

124

80 (65)

27 (22)

10 (8)

7 (5)

Sex n(%)

   Male

63 (51)

40 (50)

13 (48)

5 (50)

5 (71)

   Female

61 (49)

40 (50)

14 (52)

5 (50)

2 (29)

0.73†

Age (years)

median (IQR)

5.0 (2.1- 7.0)

4.7 (2.0 -8.6)

7.0 (5.4-9.8)

1.7 (0.9 - 2.8)

4.08(1.3 -6.6)

0.0001*^a

BAZ¥

Median (IQR)

0.29 (-2.9, -1.2)

0.42 (-0.8, 0.9)

-0.42 (-1.7, 0.4)

0.44 (0.2, 1.3)

0.37 (0.3, 1.0)

0.01*^a

WAZ¥

   median (IQR)‡

-1.2 (-2.1, - 0.5)

-1.13 (-1.9, - 0.2)

-2.10 (-2.9,-1.2)

-1.33 (-2.1, -0.6)

-0.90 (-1.1, -0.6)

0.06^a

HAZ¥

   median (IQR)

-2.0 (-2.9, -1.2)

-1.95 (-2.6, -1.1)

-2.39 (-3.2, -1.42)

- 2.55 (-3.7, -1.3)

-1.99 (-3.2, -1.5)

0.18^a

#WHO stage n (%)

   Stage1

23 (19)

14(18)

6 (22)

2 (20)

1(14)

   Stage 2

63 (51)

37(46)

17 (63)

5 (50)

4(57)

   Stage 3

38 (30)

29(36)

4 (15)

3 (30)

2(29)

0.61

WAZ category‡

   WAZ >-2

81 (72)

58 (77)

10 (48)

7 (70)

6 (100)

   WAZ <=-2

31 (28)

17 (23)

11 (52)

3 (30)

0 (0)

0.02*

HAZ category

   HAZ >-2

62 (50)

42 (53)

12 (44)

4 (40)

4 (57)

   HAZ <=-2

62 (50)

38 (47)

15 (55)

6 (60)

3 (43)

0.78

BAZ category

   BAZ >-2

117 (94)

75 (94)

25 (93)

10 (100)

7(100)

   BAZ <=-2

7 (6)

5 (6)

2 (7)

0 (0)

0 (0)

0. 75

Log₁₀ HIV-1 RNA

   median (IQR)

5.55 (5.2 - 5.8)

5.54 (5.2 - 5.9)

5.36 (4.9 - 5.7)

5.88 (5.7 - 5.9)

5.76 (5.6 - 6.2)

0.007*^a

CD4 cell %

   median (IQR)§

11.75 (7.5 - 18.0)

14.7 (10.3 -19.7)

7.2 (3.3 - 9.0)

14.6 (8.4 - 21.0)

5 (3.8 -11.1)

0.0001*^a

CD4 cell % category

n (%)

   ≤ 5%

19 (16)

6 (8)

8 (31)

1 (10)

4 (57)

   > 5% - ≤ 10%

30 (25)

13 (17)

13 (50)

3 (30)

1 (14)

   > 10%

71 (59)

58 (75)

5 (19)

6 (60)

2 (29)

< .0001*